Araştırma Çıktıları

Permanent URI for this communityhttps://hdl.handle.net/11443/931

Browse

Author: search.filters.author.Dogru-Abbasoglu, Semra

Search Results

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    The effect of 1,25-dihydroxyvitamin D3 on liver damage, oxidative stress, and advanced glycation end products in experimental nonalcoholic- and alcoholic- fatty liver disease
    (SCIENTIFIC TECHNICAL RESEARCH COUNCIL TURKEY-TUBITAK, 2021-01-01) Bingul, Ilknur; Aydin, A. Fatih; Kucukgergin, Canan; Dogan-Ekici, Isin; Dogru-Abbasoglu, Semra; Uysal, Mujdat
    Background/aim: Oxidative stress and advanced glycation end products (AGEs) formation are proposed as effective mechanisms in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD). 1,25(OH)(2)D-3 was proposed to have antioxidant, antiinflammatory and antiglycation properties. In this study, the effect of 1,25(OH)(2)D-3 treatment on oxidative stress parameters and AGEs levels together with hepatic histopathology was investigated in high fructose (HFr) or ethanol (EtOH)-treated rats. Materials and methods: Rats were treated with fructose (30\%) or ethanol (5-20\%) in drinking water with and without 1,25(OH)(2)D-3 treatment (5 mu g/kg two times a week) for 8 weeks. Insulin resistance (IR), oxidative stress parameters, AGEs, triglyceride (TG), and hydroxyproline (Hyp) levels together with histopathology were investigated in the liver. Results: 1,25(OH)(2)D-3 decreased hepatic reactive oxygen species, lipid and protein oxidation products together with histopathological improvements in HFr- and EtOH-treated rats. 1,25(OH)(2)D-3 treatment was observed to decrease significantly serum and hepatic AGEs in HFr group, and hepatic AGEs in EtOH group. Conclusion: Our results clearly show that 1,25(OH)(2)D-3 treatment may be useful in the alleviation of hepatic lesions by decreasing glycooxidant stress in both NAFLD and ALD models created by HFr- and EtOH-treated rats, respectively.
  • Thumbnail Image
    Item
    The Evaluation of Endothelin-1 and Endothelin Receptor Type A Gene Polymorphisms in Patients with Vitiligo
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2016-01-01) Bingul, Ilknur; Aydingoz, Ikbal Esen; Vural, Pervin; Dogru-Abbasoglu, Semra; Uysal, Mujdat
    Background: Endothelin-1 (EDNi) and EDN receptor type A (EDNRA) are implicated in melanocyte functions. Aim and Objectives: This study examines the role of EDN1 (G5665T and T-1370G) and EDNRA (C + 70G and G-231A) polymorphisms as a risk factor for vitiligo, and evaluates the relationship between genotypes and clinical characteristics of vitiligo patients. Materials and Methods: We analyzed genotype/alele distributions of EDN1 and EDNRA polymorphisms in 100 patients with vitiligo and 185 healthy controls by real-time polymerase chain reaction. Results: There was no notable risk for vitiligo afflicted by studied polymorphisms. However, the presence of EDNRA + 70 variant G allele was found to be related with decreased risk for development of generalized type of vitiligo (odds ratio {[}OR]: 0.42, 95\% confidence interval {[}CI] = 0.21-0.86, Por = 0.03) and showed protective effect against associated diseases seen in vitiligo (OR: 0.49, 95\% CI = 0.27-0.88, p(corr) = 0.034). Haplotype analysis demonstrated a strong (disequilibrium coefficient = 0.73, r(2) = 0.405) linkage disequilibrium between EDN1 G5665T and T-1370G polymorphisms. The EDN1 5665/-1330 TT haplotype was over represented significantly in controls than in patients (P = 0.04). Conclusion: The studied polymorphisms do not seem to be a major risk for vitiligo. Haplotype analysis denoting protective effects against vitiligo may indicate an indirect interaction in the course of vitiligo. In addition, EDNRA + 70 polymorphism is protective against generalized type of vitiligo and associated diseases.